Novartis has confirmed a patient currently on Gilenya has contracted PML. The patient has previously been on Tysabri so that just muddies up the waters.
"The current assessment is that Tysabri is the drug most likely associated with this case of PML," Novartis said in a statement. "However, a contribution of Gilenya to the evolution of this case can't be excluded."
As always, please consult with your neurologist before changing your medications.
"The current assessment is that Tysabri is the drug most likely associated with this case of PML," Novartis said in a statement. "However, a contribution of Gilenya to the evolution of this case can't be excluded."
As always, please consult with your neurologist before changing your medications.
Comment